Skip to main content
Midas Edge

MAXCYTE INC

For the period ended Dec 31, 2024. Filed Mar 11, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 11, 2025

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Changes in Stockholders’ Equity

(in thousands, except share amounts)

​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Accumulated · ​ · Stockholders’
​ · Shares · Amount · Capital · Deficit · Equity
Balance at December 31, 2022102,397,913​$1,024​$390,819​$(137,875)​$253,968
Stock-based compensation expense—​—​13,979​—​13,979
Vesting of restricted stock units​288,550​​3​​(3)​​—​​—
Issuance of common stock under employee stock purchase plan​82,423​​1​​268​​—​​269
Exercise of stock options1,192,784​12​1,862​—​1,874
Net loss—​—​—​(37,923)​(37,923)
Balance at December 31, 2023103,961,670​​1,040​​406,925​​(175,798)​​232,167
Stock-based compensation expense—​​—​​13,083​​—​13,083
Vesting of restricted stock units​418,260​​4​​(4)​​—​​—
Issuance of common stock under employee stock purchase plan​140,046​​1​​458​​—​​459
Exercise of stock options1,191,117​​12​​1,585​​—​1,597
Net loss—​​—​​—​​(41,055)​(41,055)
Balance at December 31, 2024105,711,093​$1,057​$422,047​$(216,853)​$206,251
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.